Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 102 entries
View as:

Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children

Phase: N/A Priority: Normal
NCT ID: NCT01593488 Org: User:
Start: 03/31/12 End: 12/31/24 Due: 12/31/25

Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01481545 Org: User:
Start: 12/31/06 End: 12/31/16 Due: 12/31/17

Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01074684 Org: User:
Start: 01/31/10 End: 12/01/21 Due: 12/01/22

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT05821556 Org: User:
Start: 06/12/23 End: 06/30/26 Due: 06/30/27

END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Phase: N/A Priority: Normal
NCT ID: NCT00401635 Org: User:
Start: 11/30/02 End: - Due: -

REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis

Phase: N/A Priority: Normal
NCT ID: NCT03380858 Org: User:
Start: 11/02/17 End: 05/02/19 Due: 05/02/20

MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00403429 Org: User:
Start: 03/31/06 End: 07/31/08 Due: 07/31/09

Second Look Laparoscopy in Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01628211 Org: User:
Start: 04/30/12 End: 12/31/24 Due: 12/31/25

Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05817227 Org: User:
Start: 05/19/22 End: 11/19/25 Due: 11/19/26

HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00401427 Org: User:
Start: 11/30/02 End: 12/31/06 Due: 12/31/07

MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01405586 Org: User:
Start: 03/31/11 End: 11/30/24 Due: 11/30/25

Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03874026 Org: User:
Start: 09/05/19 End: 09/30/25 Due: 09/30/26

A Phase I Trial of IMA970A Plus Montanide in Combination with Durvalumab (anti-PD-L1)

Phase: N/A Priority: Normal
NCT ID: NCT06218511 Org: User:
Start: 11/22/22 End: 11/30/26 Due: 11/30/27

VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00431704 Org: User:
Start: 10/31/07 End: 12/31/23 Due: 12/31/24

MAnagement of METastatic Disease in Campania (MAMETIC)

Phase: N/A Priority: Normal
NCT ID: NCT04595032 Org: User:
Start: 09/11/20 End: 02/08/24 Due: 02/08/25

A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures

Phase: N/A Priority: Normal
NCT ID: NCT02364791 Org: User:
Start: 02/28/15 End: 12/31/24 Due: 12/31/25

Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04129281 Org: User:
Start: 01/23/19 End: 02/23/24 Due: 02/23/25

Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)

Phase: N/A Priority: Normal
NCT ID: NCT06905262 Org: User:
Start: 01/02/23 End: 09/30/25 Due: 09/30/26

Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis

Phase: N/A Priority: Normal
NCT ID: NCT06905145 Org: User:
Start: 05/03/24 End: 05/31/32 Due: 05/31/33

PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)

Phase: N/A Priority: Normal
NCT ID: NCT04854213 Org: User:
Start: 10/06/21 End: 03/31/25 Due: 03/31/26

Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated

Phase: N/A Priority: Normal
NCT ID: NCT02069067 Org: User:
Start: 12/31/11 End: 12/31/23 Due: 12/31/24

Prediction of True Oligo-metastatic Disease.

Phase: N/A Priority: Normal
NCT ID: NCT05806151 Org: User:
Start: 01/17/23 End: 03/31/26 Due: 03/31/27

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Phase: N/A Priority: Normal
NCT ID: NCT04091204 Org: User:
Start: 07/04/19 End: 09/01/23 Due: 09/01/24

MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00401674 Org: User:
Start: 06/30/03 End: 06/30/08 Due: 06/30/09

Study on Gynecological Rare Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05733806 Org: User:
Start: 10/14/19 End: 02/01/30 Due: 02/01/31